Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 4, 2006, Pages 401-411

  Latz, Jane E ^a   Chaudhary, Ajai ^a   Ghosh, Atalanta ^a   Johnson, Robert D ^b  

^a ELI LILLY AND COMPANY   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Alimta; Cancer; Clearance; NONMEM; Pemetrexed; Population pharmacokinetics; Renal elimination

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PEMETREXED;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BODY SURFACE; CANCER; CANCER CHEMOTHERAPY; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NEUTROPENIA; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; BAYES THEOREM; BODY SURFACE AREA; CLINICAL TRIALS, PHASE II; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; NEUTROPENIA; POPULATION; REPRODUCIBILITY OF RESULTS;

EID: 30644459850     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0036-1     Document Type: Article

References (46)

1. Adjei AA (2003) Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3:145-156
2. 12) and folate deficiency. FASEB J 7:1344-1353
3. Bajetta E, Celio L, Buzzoni R et al (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14:1543-1548
4. Beal SL, Sheiner LB (1992) NONMEM users guide. NONMEM project group, University of California, San Francisco
5. 12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 20:76a
6. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
7. Chaudhary AK, Schannen V, Knadler MP, Lantz R, Le Lacheur RM (1999) Analysis of LY231514 by LC/MS/MS. Proceedings 47th ASMS conference on Mass Spectrometry Allied Topics, Dallas, TX
8. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
9. Cripps C, Burnell M, Jolivet J et al (1999) Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 10:1175-1179
10. Egorin MJ (2003) Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. J Clin Oncol 21:182-183
11. Eli Lilly and Company (2004) Package insert: Alimta, pemetrexed for injection
12. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495
13. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad, and body-surface area. Eur J Cancer 38:1677-1684
14. Goedhals L,van Wijk AL (1998) MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 9(suppl 4):70
15. Grem JL (1990) Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 180-224
16. Grindey GB, Shih C, Barnett CJ et al (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33:411
17. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
18. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. DOI 10.1007/s00280-005-0077-5
19. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. DOI 10.1007/s00280-005-0035-2
20. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528
21. McDonald AC, Vasey PA, Adams L et al (1998) A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4:605-610
22. Mentre F, Ebelin ME (1997) Validation of population pharmacokinetic/ pharmacodynamic analyses: review of proposed approaches. In: Balant LP, Aarons L (eds) The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Commission of the European Communities, Brussels, pp 147-160
23. Miller KD, Picus J, Blanke C et al (2000) Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103
24. Mita AC, Sweeney CJ, Baker SD et al (2005) A phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function [manuscript in press]
25. Niyikiza C, Baker SD, Seitz DE et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552
26. Niyikiza C, Hanauske AR, Rusthoven JJ et al (2002) Pemetrexed safety and dosing strategy. Semin Oncol 29(6 Suppl 18):24-29
27. O'Dwyer PJ, Nelson K, Thornton DE (1999) Overview of phase II trials of MTA in solid tumors. Semin Oncol 26:99-104
28. Quellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL (2000) Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother Pharmacol 46:227-234
29. Paz-Ares L, Tabernero J, Moyano A et al (1999) Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Eur J Cancer 35(suppl 2):S81
30. Pivot X, Raymond E, Laguerre B et al (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649-655
31. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16:2297-2298
32. Reilly JJ, Workman P (1993) Normalisation of anticancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32:411-418
33. Rinaldi DA (1999) Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 26(2 Suppl 6):82-88
34. Rinaldi DA, Burris HA, Dorr FA et al (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850
35. Rinaldi DA, Kuhn JG, Burris HA et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380
36. Rusthoven JJ, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1199
37. Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177
38. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561
39. Schilsky RL (1992) Antimetabolites. In: Perry MC (ed) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, pp 301-317
40. Shargel L, Yu ABC (1985) Applied biopharmaceutics, 2nd ed. Appleton-Century-Crofts, Norwalk, pp 310-312
41. Sheiner LB (1986) Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J Pharmacokinet Biopharm 14:539-555
42. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95
43. Shih C, Gosset L, Gates S et al (1996) LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition. Ann Oncol 7(Suppl 1):85
44. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ (2001) Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2:47-51
45. Sun H, Fadiran EO, Jones CD et al (1999) Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 37:41-58
46. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644